Glioblastoma Foundation Funds Nanoparticle Drug Delivery Study

The Glioblastoma Foundation is pleased to announce the funding of a new nanoparticle delivery study for glioblastoma at Yale University. Dr. Mark Saltzman, Professor of Biomedical Engineering, and Physiology, at the Yale Cancer Center is leading a study to develop  nanoparticles to target microRNAs, which regulate cancer gene expression.

Drug delivery to the site of glioblastoma tumors has always been challenging. The Glioblastoma Foundation is supportive of new drug delivery techniques, and the use of nanoparticles as a vehicle for drug delivery to the site of the tumor presents an exciting potential new treatment modality moving forward.

Dr. Saltzman's research is focused on developing drug delivery vehicles for life-threatening cancers.

"Nanoparticles are used to target the microRNAs and bypass the blood brain barrier and deliver the drug directly to the tumor," he said.

Dr. Saltzman's research aims to promote new methods of drug delivery and develop biotechnologies to combat disease.

He is the founding Chair of the Department of Biomedical Engineering at Yale University and has pioneered advancements in the fields of biomaterials and tissue engineering. He also helped create the Gliadel wafer that has been used for glioblastoma.

The Glioblastoma Foundation would like to thank Dr. Saltzman and his team for their dedication to glioblastoma and to furthering our understanding of drug-delivery techniques for glioblastoma.

To learn more about the Glioblastoma Foundation, please visit our About Us page.

The Glioblastoma Foundation is the most trusted name in research funding for leading edge therapies to transform glioblastoma outcomes for all patients.

©2023 Glioblastoma Foundation. All rights reserved.

The current standard of care for glioblastoma consisting of radiation and chemotherapy is ineffective.

Help Us Transform Glioblastoma Therapy